rotating globe
17 Nov 2026


Mankind Pharma licenses Ensartinib for India’s cancer market

Deal adds targeted therapy for adults with advanced ALK-positive lung cancer patients

Mankind Pharma has strengthened its presence in the cancer treatment segment by entering into an exclusive licensing agreement with China-based Betta Pharmaceuticals for ensartinib, a targeted therapy used to treat a specific type of advanced lung cancer. The agreement marks an important step in the Indian pharmaceutical company’s efforts to expand beyond its traditional generics and over-the-counter (OTC) medicines business and build a stronger presence in specialised oncology treatments.

Under the agreement, Mankind Pharma will secure exclusive rights to develop, manufacture, register and commercialise ensartinib in India. The drug is intended for adult patients diagnosed with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received treatment with an ALK inhibitor.

Ensartinib has already received approval from the United States Food and Drug Administration (US FDA) and China’s National Medical Products Administration (NMPA). However, its introduction in India will depend on the necessary regulatory approvals and completion of commercial and operational requirements.

The financial details of the licensing agreement have not been disclosed. Mankind Pharma will make an upfront payment to Betta Pharmaceuticals, followed by potential development and sales milestone payments. The agreement also includes royalty payments calculated on the drug’s annual net sales in India.

The partnership brings together Mankind Pharma’s pharmaceutical capabilities and Betta Pharmaceuticals’ experience in developing innovative cancer treatments. It is also expected to help the Indian drugmaker expand its capabilities in specialised therapies and strengthen its position in the growing oncology market.

Atish Majumdar, Senior President of Mankind Pharma, said the agreement reflects the company’s ambition to build a differentiated oncology portfolio and bring innovative treatments into its growth strategy. He said the licensing arrangement would help accelerate its expansion into oncology, strengthen its therapeutic capabilities and support efforts to make advanced treatment options available to patients in India.

Shizhe Ding, Chairman Assistant and Head of Business Development at Betta Pharmaceuticals, said the partnership would help extend the reach of ensartinib to a wider patient population by combining the strengths of both companies.

Ensartinib belongs to a class of medicines known as targeted cancer therapies. Unlike conventional chemotherapy, which can affect both cancerous and healthy cells, targeted treatments are designed to interfere with specific molecular changes that help cancer cells grow and survive.

The drug works by blocking the activity of anaplastic lymphoma kinase (ALK), a protein that can contribute to the development and spread of cancer in certain patients. In some cases of non-small cell lung cancer, changes in the ALK gene cause the protein to become abnormally active, encouraging cancer cells to multiply.

ALK-positive lung cancer is a distinct molecular subtype of non-small cell lung cancer. Identifying this genetic alteration through appropriate diagnostic testing helps doctors determine whether patients could benefit from ALK-targeted medicines.

Ensartinib is particularly intended for patients whose cancer has progressed locally or spread to other parts of the body and who have not previously received an ALK inhibitor. Its oral formulation also makes it a treatment that can be administered in tablet form.

The US FDA approved ensartinib in December 2024 for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who had not previously received ALK-targeted treatment.

The approval was supported by findings from the Phase 3 eXALT3 clinical trial, which compared ensartinib with crizotinib, another targeted lung cancer medicine. The study involved 290 patients and demonstrated a significant improvement in progression-free survival among those receiving ensartinib.

According to the FDA, the median progression-free survival was 25.8 months for patients treated with ensartinib, compared with 12.7 months for those receiving crizotinib. Progression-free survival refers to the period during which a patient lives without the disease worsening.

However, the trial did not establish a statistically significant improvement in overall survival. The most commonly reported side effects included skin rash, muscle and joint pain, constipation, cough, itching, nausea, swelling, fever and fatigue.

These findings provide the clinical background for the drug’s international regulatory approval, although treatment decisions must be based on individual patient assessments and medical advice.

The ensartinib agreement is part of Mankind Pharma’s broader strategy to increase its presence in innovative medicines and specialised treatments. The company has traditionally built its business around affordable generic medicines and consumer healthcare products. Its latest move indicates a growing interest in therapies that address complex diseases, including cancer.

The company has also made investments and entered into licensing arrangements to expand its specialised medicine portfolio. Its investment in Armed Cell Therapeutics, a developer working on dual-target CAR-T therapies for multiple myeloma, was another recent step towards building capabilities in advanced cancer treatment.

Mankind has also entered into an agreement with China’s Chenan Biopharmaceutical for insulin degludec and a combination of insulin degludec and insulin aspart. These agreements reflect its increasing reliance on international partnerships to access specialised drug candidates and expand its treatment offerings.

The latest development also comes as Indian pharmaceutical companies increasingly look towards China for innovative drug candidates. Chinese pharmaceutical companies have expanded their research and development capabilities in recent years, creating opportunities for partnerships with international drugmakers.

Indian companies are seeking to access these developments through licensing agreements rather than relying entirely on in-house research and drug discovery.

For Mankind Pharma, the ensartinib deal offers an opportunity to enter a specialised segment of lung cancer treatment while leveraging an already approved international drug candidate.

Ensartinib will enter an established and competitive market for ALK-positive lung cancer treatments. Several international pharmaceutical companies already have targeted medicines in this segment, including Pfizer’s Lorbrena, Roche’s Alecensa and Novartis’s Zykadia. Takeda’s Alunbrig is another drug in the ALK inhibitor category.

The presence of established treatments means Mankind Pharma will need to focus on regulatory clearances, pricing, market access and relationships with oncology specialists as it prepares to introduce the medicine in India.

The licensing agreement also reflects a wider shift in the pharmaceutical industry, where Indian companies are increasingly partnering with Chinese drug developers to bring new cancer therapies into their markets.

Other Indian pharmaceutical companies have pursued similar arrangements. Glenmark Pharmaceuticals licensed a cancer drug candidate from China’s Hengrui Pharmaceuticals, while Cipla entered into a licensing agreement with a Chinese pharmaceutical company for an antibody-drug conjugate, rolditamig deruxtecan. These developments highlight the growing importance of China-originated drug innovation in the global pharmaceutical sector.